Optimal GNG decision rules for an adaptive seamless Ph2/3 oncology trial
Optimal GNG decision rules for an adaptive seamless Ph2/3 oncology trial . Cong Chen Linda Sun BARDS, Merck & Co., Inc. Typical situation in oncology. Success rate in Ph3 is low, cost for Ph3 is high and competition is fierce Data at Ph2 to Ph3 transition point
329 views • 27 slides